Dear Editor, Combination of bendamustine plus rituximab (BR) has become one of the standard regimens for patients with low-grade lymphomas. In several randomized clinical trials that established the efficacy and safety of BR [1, 2] , infectious episodes in patients given with BR were comparable to or less frequent than those with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) [1] , or rituximab plus cyclophosphamide, vincristine, and prednisone (R-CVP) [2] . However, several papers emphasize the immunosuppressive effects of bendamustine that increase the risk of opportunistic infections [3] [4] [5] . Reactivation of cytomegalovirus has been observed in up to 20 % of those treated with bendamustine-containing chemotherapies [4, 5] . Late occurrence of progressive multifocal leukoencephalopathy (PML) by JC virus was also described [6] , although the other drugs combined with bendamustine may also contribute to the immunosuppressive state of these patients. Here, we present a patient who developed Epstein-Barr virus (EBV)-associated lymphoproliferative disorder.
A 62-year-old woman was referred to our hospital in 2013 because of right-sided enlargement of the tonsil. Pathological examination of the tonsil showed marked proliferation of small-or medium-sized centrocytes and centroblasts, expressing CD10, CD20, CD79a, BCL2, and BCL6 with follicle-like architecture. A diagnosis of follicular lymphoma, grade2A, stage IIIA was given based on 18 F-FDG PET/CT scan and bone marrow examination. She received 6 cycles of BR; 2 months after the completion, CT scan showed complete remission. Fourteen months after the chemotherapy, she noticed lymphadenopathy in the right cervix and the right axilla.
18
F-FDG PET/CT scan showed glucose uptake on the bilateral cervical and the right axillary lymph nodes. Pathological examination of the right axillary lymph node showed almost preserved architecture with follicular enlargement (Fig. 1a) . Also, BCL2-positive cells were restricted to the interfollicular area (Fig. 1b) , and scattered CD30-positive large cells were present in the same area (Fig. 1c) . Epstein-Barr encoding region (EBER) in situ hybridization revealed that EBV-infected cells were scattered in both the interfollicular area and germinal center, resembling early lesions of post-transplant lymphoproliferative disorder (PTLD) (Fig. 1d) . Quantitative analysis of EBV load using a real-time PCR assay detected 1069 copies per microgram DNA in peripheral blood mononuclear cells. Hence, we concluded that she developed EBVassociated lymphoproliferative disorder (LPD), which was attributable to the immunosuppressive state as a result of BR therapy.
Iatrogenic LPDs are lymphoproliferations or lymphomas that arise in patients treated with immunosuppressive drugs [7] , such as methotrexate and anti-TNF antibodies. EBV is frequently detected in iatrogenic LPDs as is in other LPDs [7] . This case shows that EBV reactivation and subsequent EBV-associated LPD may occur 14 months after the bendamustine-containing treatment. Follicular lymphomas frequently relapse after the completion of chemotherapies. Biopsy of tumors and monitoring of EBV load may be helpful to properly discriminate EBV-associated LPD from recurrence of follicular lymphomas. 
